These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8347490)

  • 1. Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators.
    Seymour L; Bezwoda WR
    Br J Cancer; 1993 Aug; 68(2):352-6. PubMed ID: 8347490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients.
    Toma S; Raffo P; Nicolo G; Canavese G; Margallo E; Vecchio C; Dastoli G; Iacona I; Regazzi-Bonora M
    Int J Oncol; 2000 Nov; 17(5):991-1000. PubMed ID: 11029503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer.
    Seymour L; Bezwoda WR
    Breast Cancer Res Treat; 1994; 32(2):229-33. PubMed ID: 7865852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor-alpha and endocrine sensitivity in breast cancer.
    Nicholson RI; McClelland RA; Gee JM; Manning DL; Cannon P; Robertson JF; Ellis IO; Blamey RW
    Cancer Res; 1994 Apr; 54(7):1684-9. PubMed ID: 8137282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of interferon alpha-2a on hormone receptor status in patients with advanced breast cancer.
    Kornek G; Reiner A; Sagaster P; Stierer M; Mayer A; Ludwig H
    Cancer Invest; 1999; 17(3):189-94. PubMed ID: 10099657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.
    Clarke RB; Laidlaw IJ; Jones LJ; Howell A; Anderson E
    Br J Cancer; 1993 Mar; 67(3):606-11. PubMed ID: 8439511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer.
    Noguchi S; Motomura K; Inaji H; Imaoka S; Koyama H
    Cancer; 1993 Jul; 72(1):131-6. PubMed ID: 8508397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-beta 1 in metastatic human breast cancer: an immunocytochemical study.
    Murray PA; Gomm J; Ricketts D; Powles T; Coombes RC
    Eur J Cancer; 1994; 30A(9):1218-22. PubMed ID: 7999402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.
    Nicholson RI; McClelland RA; Gee JM; Manning DL; Cannon P; Robertson JF; Ellis IO; Blamey RW
    Breast Cancer Res Treat; 1994 Jan; 29(1):117-25. PubMed ID: 7912565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
    Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
    Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunocytochemical determination of estrogen and progesterone receptors on 219 fine-needle aspirates of breast cancer. A prospective study.
    Marrazzo A; Taormina P; Leonardi P; Lupo F; Filosto S
    Anticancer Res; 1995; 15(2):521-6. PubMed ID: 7763033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
    Archer SG; Eliopoulos A; Spandidos D; Barnes D; Ellis IO; Blamey RW; Nicholson RI; Robertson JF
    Br J Cancer; 1995 Nov; 72(5):1259-66. PubMed ID: 7577479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.
    DeFriend DJ; Howell A; Nicholson RI; Anderson E; Dowsett M; Mansel RE; Blamey RW; Bundred NJ; Robertson JF; Saunders C
    Cancer Res; 1994 Jan; 54(2):408-14. PubMed ID: 8275477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma.
    Bozzetti C; Nizzoli R; Naldi N; Manotti L; Savoldi L; Camisa R; Guazzi A; Cocconi G
    Breast Cancer Res Treat; 1994; 32(2):221-8. PubMed ID: 7865851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
    Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD
    Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.
    Detre SI; Ashley S; Mohammed K; Smith IE; Powles TJ; Dowsett M
    Cancer Prev Res (Phila); 2017 Mar; 10(3):171-176. PubMed ID: 28100469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
    Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
    Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
    J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.